{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T18:07:58Z","timestamp":1715969278605},"reference-count":14,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2002,1,12]],"date-time":"2002-01-12T00:00:00Z","timestamp":1010793600000},"content-version":"vor","delay-in-days":286,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2001,4]]},"abstract":"<jats:p>Use of asparaginase (ASNase) in the treatment of relapsed childhood acute lymphoblastic leukaemia (ALL) is associated with a high rate of hypersensitive reactions. \u2018Silent\u2019 inactivation may additionally reduce treatment intensity. Therefore, PEG\u2010ASNase (Oncaspar<jats:sup><jats:sc>tm<\/jats:sc><\/jats:sup>), a polyethylene glycol conjugate of the native <jats:italic>Escherichia coli<\/jats:italic>\u2010ASNase, was introduced into the Berlin\u2010Frankfurt\u2010M\u00fcnster (BFM) 96 treatment protocol for relaped ALL under drug monitoring conditions. A single i.v. dose of 500 IU\/m<jats:sup>2<\/jats:sup> PEG\u2010ASNase, substituted for the native ASNases, was administered to supply a plasma activity of 100 IU\/l for 1 week. From November 1997 to March 2000, 35 patients from 23 BFM\u2010associated hospitals, with or without a previous allergic reaction to one or both native preparations, underwent monitoring. After 82 applications, a total of 270 samples were submitted to be tested for ASNase activity. The ASNase activity on the day of the administration and the following day ranged between &lt;\u200a20 and 693 IU\/l, with a median of 413 IU\/l (53 samples). The median on d\u20037\u2003\u00b1\u20031 was 199 IU\/l (range &lt;20\u2013421 IU\/l; 41 samples) and on d\u200314\u2003\u00b1\u20031, 105 IU\/l (range &lt;20\u2013188 IU\/l; 19 samples). An ASNase activity of &gt;\u200a100 IU\/l was seen on d\u20037 in 36 activity time courses of 52 interpretable applications (69%). Intraindividual variability of activity time courses was low. However, a rapid decrease in ASNase activity after repeated applications was observed in 4 out of 20 children. Previously experienced allergic reactions to native ASNases did not influence PEG\u2010ASNase pharmacokinetics. PEG\u2010ASNase is a useful alternative to the native ASNases in children with relapsed ALL. Whenever possible, drug monitoring should be performed to identify patients with \u2018silent\u2019 inactivation.<\/jats:p>","DOI":"10.1046\/j.1365-2141.2001.02680.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T06:33:10Z","timestamp":1047364390000},"page":"115-119","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Drug monitoring of low\u2010dose PEG\u2010asparaginase (Oncaspar<sup><scp>tm<\/scp><\/sup>) in children with relapsed acute lymphoblastic leukaemia"],"prefix":"10.1111","volume":"113","author":[{"given":"J. P","family":"Vieira Pinheiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. J.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Schwabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gunkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Casimiro da Palma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Henze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Von Sch\u00fctz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Winkelhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"W\u00fcrthwein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Boos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,12]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.9.1780"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920701)70:1<201::AID-CNCR2820700131>3.0.CO;2-M"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03259347"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(96)00131-1"},{"key":"e_1_2_6_6_1","first-page":"115","article-title":"Asparaginase\u2010methotrexate in combination chemotherapy: Schedule\u2010dependent differential effects on normal versus neoplastic cells","volume":"65","author":"Capizzi R.L.","year":"1981","journal-title":"Cancer Treatment Reports"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010722"},{"key":"e_1_2_6_8_1","first-page":"349","article-title":"Clinical\u00a0pharmacology of polyethylene glycol\u2010l\u2010asparaginase","volume":"14","author":"Ho D.H.","year":"1986","journal-title":"Drug Metabolism and Disposition"},{"issue":"1","key":"e_1_2_6_9_1","first-page":"59","article-title":"A new look at PEG\u2010l\u2010asparaginase and other asparaginases in hematological malignancies","volume":"12","author":"Kurtzberg J.","year":"1994","journal-title":"Cancer Investigation"},{"key":"e_1_2_6_10_1","first-page":"304","article-title":"Antibodies to asparaginase alter pharmacokinetics and decrease enzyme activity in patients on asparaginase therapy","volume":"34","author":"Kurtzberg J.","year":"1993","journal-title":"Proceedings of the American Association for Cancer Research"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(98)00015-8"},{"key":"e_1_2_6_12_1","first-page":"4554","article-title":"l\u2010asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans","volume":"41","author":"Riccardi R.","year":"1981","journal-title":"Cancer Research"},{"key":"e_1_2_6_13_1","first-page":"1313","article-title":"l\u2010asparaginase\u2010induced modulation of methotrexate polyglutamylation in murine leukemia L5178Y","volume":"47","author":"Sur P.","year":"1987","journal-title":"Cancer Research"},{"key":"e_1_2_6_14_1","doi-asserted-by":"crossref","unstructured":"Werber G. Ahlke E. Nowak\u2010G\u00f6ttl U. J\u00fcrgens H. Verspohl E.J.&Boos J.(1997)Asparaginase activities in vitro are highly sensitive to different buffer conditions.Acute Leukemias. VI. Prognostic Factors and Treatment Strategies(Ed. by B\u00fcchner et al.) pp.512\u2013516.Springer Verlag. Berlin.","DOI":"10.1007\/978-3-642-60377-8_81"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.7.1525"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.02680.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.02680.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.2001.02680.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T09:52:57Z","timestamp":1697536377000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.2001.02680.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,4]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,4]]}},"alternative-id":["10.1046\/j.1365-2141.2001.02680.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.2001.02680.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,4]]},"assertion":[{"value":"2002-01-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}